Additional Relevant Details Bristol-Myers Squibb's recently acquired Promedior Inc. has advanced its lead therapeutic PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF) into Phase 2 clinical studies.  The ongoing Phase 2 trial is a multi-center, two stage, adaptive design study to determine the efficacy and safety of PRM-151 as a single agent or added to a stable dose of ruxolitinib in patients with various conditions of MF.  The study is expected to complete in 2017.